USD 0.24
(23.87%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 621.48 Million USD | -7.54% |
2022 | 672.14 Million USD | -13.4% |
2021 | 776.15 Million USD | 249.95% |
2020 | 221.79 Million USD | 83.37% |
2019 | 120.95 Million USD | 76451.9% |
2018 | 158 Thousand USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 594.79 Million USD | -2.99% |
2024 Q1 | 613.12 Million USD | -1.35% |
2023 Q4 | 621.48 Million USD | -1.49% |
2023 FY | 621.48 Million USD | -7.54% |
2023 Q1 | 657.05 Million USD | -2.24% |
2023 Q2 | 641.41 Million USD | -2.38% |
2023 Q3 | 630.87 Million USD | -1.64% |
2022 Q4 | 672.14 Million USD | -2.09% |
2022 Q3 | 686.48 Million USD | -4.62% |
2022 Q2 | 719.73 Million USD | -4.27% |
2022 Q1 | 751.8 Million USD | -3.14% |
2022 FY | 672.14 Million USD | -13.4% |
2021 Q3 | 797.79 Million USD | -2.02% |
2021 FY | 776.15 Million USD | 249.95% |
2021 Q4 | 776.15 Million USD | -2.71% |
2021 Q2 | 814.26 Million USD | -2.14% |
2021 Q1 | 832.05 Million USD | 275.15% |
2020 FY | 221.79 Million USD | 83.37% |
2020 Q2 | 106.93 Million USD | 0.0% |
2020 Q4 | 221.79 Million USD | 123.08% |
2020 Q3 | 99.42 Million USD | -7.03% |
2020 Q1 | - USD | -100.0% |
2019 FY | 120.95 Million USD | 76451.9% |
2019 Q4 | 120.95 Million USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | 158 Thousand USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ADC Therapeutics SA | 354.78 Million USD | -75.173% |
Alto Neuroscience, Inc. | 86.62 Million USD | -617.417% |
Annovis Bio, Inc. | 10.2 Million USD | -5988.048% |
Biohaven Pharmaceutical Holding Company Ltd. | 513.21 Million USD | -21.097% |
Ginkgo Bioworks Holdings, Inc. | 1.66 Billion USD | 62.681% |
Nuvation Bio Inc. | 621.48 Million USD | 0.0% |
Arcus Biosciences, Inc. | 1.09 Billion USD | 43.243% |
Theriva Biologics, Inc. | 60.21 Million USD | -932.177% |
Zymeworks Inc. | 580.88 Million USD | -6.99% |